Novavax's partners have secured approvals for their Nuvaxovid vaccine, targeting the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in key markets. This development ensures Novavax will continue to receive royalties from net sales in these regions, providing a stable revenue stream for the company.
Novavax's partners have successfully obtained approvals for the Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., EU, and Japan. This is a positive development for Novavax as it confirms a continued revenue stream through royalties on net sales in these significant markets. The approvals ensure Novavax remains a player in the evolving COVID-19 vaccine landscape, providing some stability to its financial outlook. For traders, this reduces uncertainty around future royalty income, potentially supporting the stock in the short to medium term, though the long-term impact will depend on vaccine uptake and competitive landscape.